Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s interests, with Duchini, through Kelbury Pty Ltd, acquiring 416,667 fully paid ordinary shares at $0.12 per share in a recent placement. Following the transaction, his indirect holding increased to 1,732,456 shares while his direct holding of 960,000 unlisted options remained unchanged, signalling continued insider support for the company’s capital raising efforts and potentially reinforcing market confidence in its strategic direction.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company focused on developing therapeutics in the pharmaceutical and life sciences sector. The company is listed on the ASX and operates in drug development, targeting neurological or related therapeutic areas under its corporate structure.
Average Trading Volume: 773,723
Technical Sentiment Signal: Sell
Current Market Cap: A$64.51M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.